Medical devices approved first in the European Union (EU) are associated with a greater rate of safety issues, finds a study published by The BMJ today.
Clinical trial results for many new medical devices that could guide treatment decisions also remain unpublished or unavailable up to five years after approval, the findings show.
As such, the researchers call for greater regulatory transparency to enable patients and clinicians to make informed decisions about treatment.